Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Xin Huanghe Pharmaceutical Co., Ltd., explained in plain language.
-
Can a Three-Drug inhaler outperform the standard Two-Drug treatment for asthma?
Disease control CompletedThis trial tests whether CP006, an investigational inhaler combining three medications (budesonide, formoterol, and umeclidinium), improves lung function in adults with asthma better than a standard two-drug inhaler. Participants take either a high or low dose of CP006 or the com…
Phase 2 • Sponsor: Shanghai Xin Huanghe Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 09, 2026 17:58 UTC
-
Can a new inhaler match symbicort for asthma control?
Disease control CompletedThis Phase 3 trial tests whether a new budesonide/formoterol dry powder inhaler works as well as the established Symbicort Turbuhaler in adults with asthma. About 338 participants will take either the test inhaler or Symbicort twice daily for six weeks. Researchers will measure c…
Phase 3 • Sponsor: Shanghai Xin Huanghe Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new inhaler match Symbicort's performance?
Knowledge-focused CompletedThis trial tests whether a new formulation of budesonide and formoterol inhalation powder delivers the same amount of medication into the body as the approved Symbicort Turbuhaler. Healthy adults aged 18 to 45 will receive a single dose of each inhaler in random order, with a 4-d…
Phase 1 • Sponsor: Shanghai Xin Huanghe Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC